Table 4 Subgroup analysis of PFS and OS in non-small cell lung cancer patients with multiple therapies
Study name | Year | Treatment | Cancer type | Media PFS (months) | Z-Value | P-Value | Media PFS (months) | Z-Value | P-Value |
|---|---|---|---|---|---|---|---|---|---|
2018 | mogamulizumab +docetaxel | NSCLC | 2.243 (95% CI:1.235–3.250) | 4.364 | 0.000 | 7.335 (95% CI:5.657–9.013) | 8.570 | 0.000 | |
Doi, T | 2019 | mogamulizumab +nivolumab | NSCLC | 2.600 (95% CI:1.669–3.531) | 5.473 | 0.000 | 6.075 (95% CI:4.838–7.312) | 9.629 | 0.000 |
Overall |  |  |  | 2.435 (95% CI:1.752–3.119) | 6.982 | 0.000 | 6.519 (95% CI:5.523–7.514) | 12.836 | 0.000 |